88555-40-2

Upstream product

• 22118-09-8 2-bromoacetyl chloride 
• 21282-90-6 6-(4-aminophenyl)-4,5-dihydro-3(2H)-pyridazinone 

Downstream Products

• 111794-04-8 2-[3-(2-Cyano-phenoxy)-2-hydroxy-propylamino]-N-[4-(6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenyl]-acetamide 
• 111794-00-4 2-[2-Hydroxy-3-(2-methoxy-phenoxy)-propylamino]-N-[4-(6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenyl]-acetamide 
• 111794-24-2 2-[2-Hydroxy-3-(naphthalen-1-yloxy)-propylamino]-N-[4-(6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenyl]-acetamide 
• 111793-97-6 2-(2-Hydroxy-3-o-tolyloxy-propylamino)-N-[4-(6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenyl]-acetamide 
• 111794-40-2 2-{Benzyl-[2-hydroxy-3-(2-methoxy-phenoxy)-propyl]-amino}-N-[4-(6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenyl]-acetamide 
• 111794-42-4 2-{Benzyl-[3-(2-cyano-phenoxy)-2-hydroxy-propyl]-amino}-N-[4-(6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenyl]-acetamide 
• 111794-38-8 2-[Benzyl-(2-hydroxy-3-o-tolyloxy-propyl)-amino]-N-[4-(6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenyl]-acetamide 
• 111794-52-6 2-{Benzyl-[2-hydroxy-3-(naphthalen-1-yloxy)-propyl]-amino}-N-[4-(6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenyl]-acetamide 
• 39754-17-1 N-benzyl-glycine 4-(6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-anilide 

Relevant academic research and scientific papers

Design and synthesis of a series of combined vasodilator/β-adrenoceptor antagonists based on 6-arylpyridazinones

A series of new 6-[4-[[(aryloxy)acyl]amino]phenyl]-4,5-dihydropyridazinones have been synthesized and evaluated as combined vasodilator/β-adrenoceptor antagonists and potential antihypertensive agents. Many of the early compounds displayed an unacceptably high level of intrinsic sympathomimetic activity (ISA) and a relatively short duration of action. Disubstitution in the 2,3-positions or in the 4-position of the aryloxy ring gave compounds with low ISA levels and, in some instances, improved duration of action. All of the compounds were vasodilators, but the 5-methylpyridazinone derivatives showed consistently greater antihypertensive activity than their 5-H lower homologues. Further detailed pharmacological investigations led to the selection of 6-[4-[3-[[2-hydroxy-3-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]propyl]amino ]propionamido]phenyl]-5-methyl-4,5-dihydro-3(2H)-pyridazinone (4t) (SK&F 95018) as a development candidate.